Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies-Reference-Cited by-同舟云学术

Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies

Published:2018-09-06 Issue:12 Volume:67 Page:1833-1844
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Dobry Allison S.,Zogg Cheryl K.,Hodi F. Stephen,Smith Timothy R.,Ott Patrick A.,Iorgulescu J. Bryan^ORCID

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-018-2241-x/fulltext.html

Reference35 articles.

1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30. https://doi.org/10.3322/caac.21332

2. Glazer AM, Winkelmann RR, Farberg AS, Rigel DS (2017) Analysis of trends in US melanoma incidence and mortality. JAMA Dermatol 153:225–226. https://doi.org/10.1001/jamadermatol.2016.4512

3. Eggermont AM, Spatz A, Robert C (2014) Cutaneous melanoma. Lancet 383:816–827. https://doi.org/10.1016/S0140-6736(13)60802-8

4. Force J, Salama AK (2017) First-line treatment of metastatic melanoma: role of nivolumab. ImmunoTargets Ther 6:1–10. https://doi.org/10.2147/ITT.S110479

5. Ascierto PA, McArthur GA, Dréno B et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248–1260. https://doi.org/10.1016/S1470-2045(16)30122-X

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence and mortality trends of primary cutaneous melanoma: A 50-year Rochester Epidemiologic Project study;JAAD International;2024-09

2. Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy;Discover Oncology;2024-08-11

3. Disparities in Survival Outcomes Among Patients With Metastatic Melanoma in Texas;American Journal of Clinical Oncology;2024-06-28

4. Patterns of immunotherapy utilization for non-small cell lung cancer in Texas pre- and post-regulatory approval;Clinical and Translational Oncology;2024-03-30

5. Targeting HDAC6 improves anti-CD47 immunotherapy;Journal of Experimental & Clinical Cancer Research;2024-02-27